What is PregLem?
Founded in 2006 by Ernest Loumaye and Eric Rolin, PregLem operates at the intersection of clinical research and commercial pharmaceutical development. The company specializes in addressing unmet medical needs in gynaecology and infertility, leveraging a robust Scientific Advisory Board composed of leading European academic experts. PregLem's operational model integrates regulatory affairs with sophisticated sales and marketing strategies, allowing it to bridge the gap between laboratory innovation and patient-centric healthcare solutions. Its strategic location near Lake Geneva has facilitated deep integration into the European biotech ecosystem, enabling the firm to attract substantial institutional capital to support its mission of transforming reproductive health standards.
How much funding has PregLem raised?
PregLem has raised a total of $59.9M across 2 funding rounds:
Series A
$26.9M
Series B
$33M
Series A (2007): $26.9M with participation from MVM Partners and Sofinnova Partners
Series B (2007): $33M led by Sofinnova Ventures and MVM Life Science Partner
Key Investors in PregLem
MVM Partners
MVM Partners is a healthcare-focused investment firm with a global footprint, specializing in medical technology and pharmaceutical growth to address significant unmet clinical needs.
Sofinnova Partners
Sofinnova Partners is a premier European venture capital firm that provides hands-on support to life science companies, guiding them from early-stage development to successful market exits.
What's next for PregLem?
The strategic deployment of capital has enabled PregLem to mature its clinical assets, effectively transitioning from a research-focused entity to a commercially viable enterprise. Following its successful funding rounds, the company has demonstrated the operational maturity required to attract major industry players, as evidenced by its acquisition by Gedeon Richter Plc. Moving forward, the integration into the Richter Group provides the necessary infrastructure to scale the commercialization of its innovative drug portfolio. This evolution highlights the efficacy of the company's initial growth strategy, which prioritized high-impact clinical development and strong institutional partnerships to ensure long-term market relevance in the competitive women's health sector.
See full PregLem company page
